Psoriasis, green light from Aifa for reimbursement of deucravacitinib for moderate and severe forms

2024-09-19 17:12:15

September 19, 2024 | 19.12

COUNT: 0 minutes

People with moderate to severe psoriasis now have a new treatment option. This is deucravacitinib, a first-in-class tyrosine kinase inhibitor drug for which the Italian Medicines Agency (Aifa) has approved reimbursement. The green light from Aifa came at the center of a press conference organized by Bristol Myers Squibb in Rome.